Andreana N. Holowatyj, PhD, MS, Details the Main Results of Research into Colorectal Cancer Disparities


The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.

In a conversation with CancerNetwork®, Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke about the main takeaways from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on tumor mutation burden by race and disparities in early-onset colorectal cancer.


One of the things that we undertook in our analysis was to explore potential differences in tumor mutation burden by race within the population of early-onset colorectal cancer cases. And what we observed in doing so was that compared with young non-Hispanic Whites with a microsatellite stable colorectal tumor, we saw that young non-Hispanic Blacks actually had a significantly higher tumor mutation burden. However, when compared again with [non-Hispanic] Whites, there was no difference in tumor mutation burden with Asian or Pacific Islanders diagnosed with early-onset disease. Seeing this significantly higher tumor mutation burden in young [non-Hispanic] Blacks was quite striking and warranted further study.


Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content